Roche’s Virtual ADA Investor Event
Roche has hosted a virtual event on Monday, 8 June 2026.
| Agenda | |
|---|---|
| Introduction | Bruno Eschli, Head of Investor Relations |
| Roche obesity strategy | Morten Lammert, Global Therapeutic Area Head Cardiovascular, Renal & Metabolism |
| Obesity pipeline overview | Manu Chakravarthy, SVP, Global Head of Product Development Cardiovascular, Renal & Metabolism |
| Enicepatide Ph II (103) results in obesity | Ildiko Lingvay, MD, MPH, MSCS; Tenured Professor of Medicine in Endocrinology; External consultant to Roche and Genentech |
| Petrelintide Ph II (ZUPREME-1) results in obesity | Louis J. Aronne, MD; Past-President of the Obesity Society, Founder and Chair Emeritus of the American Board of Obesity Medicine and Endowed Professor of Metabolic Research; External consultant to Roche and Genentech |
| Q&A |
Webinar Replay
Please click the video below to watch the replay of the webinar.
Investors